Roswell Park study suggests additional applications for FL118 as personalized therapy for cancer

A team led by Fengzhi Li, PhD, and Xinjiang Wang, PhD, of Roswell Park Cancer Institute has reported new findings regarding therapeutic targets of the novel anticancer agent FL118. Previous studies from these researchers have showed that FL118 induces cancer cell death, or apoptosis, by inhibiting expression of multiple cell-survival proteins (survivin, Mcl-1, XIAP or cIAP2). Study results published in Cancer Research showed that FL118 can also activate the p53 tumor-suppressor pathway in cancer cells, encouraging cell senescence, or aging. Read more here.